Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

The stock was trading down more than 5.5% at the time of writing following the revelation that in the REDEFINE 2 trial, CagriSema (cagrilintide and semaglutide) achieved a weight loss of 15.7% ...

Headline results from a REDEFINE-2 late-stage trial released earlier this month showed that Novo's next-generation CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15. ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...